Cell Therapeutics, Inc.

Marc J McKennon

J Peter Klein

Michael Coon

Marco Artico

Giovanni Da Re

Mario Grugni

Gianluca Pardi

Valeria Livi

Luigi Siviero

Luca Feliciotti

Holly Spoonemore

Stefano Fazioni

Keith Hovda

The invention relates to an improved process for the preparation of poly-&#x3b1;-glutamic acids which comprises the polymerization of tertiary &#x3b3;-esters of &#x3b1;-glutamic acid N-carboxy anhydride with appropriate solvents and initiators, followed by acid hydrolysis of the resulting poly-&#x3b1;-glutamic acid-&#x3b3;-ester. The process is particularly advantageous in that it allows one to carefully control the molecular weight of the resulting poly-&#x3b1;-glutamic acid. The invention also relates to poly-&#x3b1;-glutamic acids capped at the amino terminus with carboxylic acids or amino acids and to a process for the preparation thereof.

Process for the preparation of poly-&#x3b1;-glutamic acid and derivatives thereof

The invention relates to a method for determining the amount of conjugated taxane, in particular paclitaxel, in a PGA-taxane conjugate said method comprising: a) reacting the PGA-taxane conjugate with a compound formula (I): RRN&#x2014;NH(I), wherein Rand Rare as defined in the description; to give a unbound taxane and a PGA hydrazide and b) determining the amount of unbound taxane.

Method for determining the amount of conjugated taxane in polyglut acid-taxane conjugates

Novel pyridopyrimidine-based compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

Pyridopyrimidine compounds and their uses

Growing community of inventors

Bellevue, WA, United States of America

Marc J McKennon